Hydroxychloroquine, a medication commonly used for malaria and autoimmune diseases like lupus and rheumatoid arthritis, is now being studied as a potential treatment for Primary Progressive Multiple Sclerosis (PPMS). This innovative approach, known as drug repurposing, explores new therapeutic uses for existing medications.
In PPMS, the chronic activation of microglia—immune cells in the central nervous system—plays a role in damaging nerve cells. Studies suggest that hydroxychloroquine can reduce disease activity by lowering microglial activation. This has shown promising results in animal models.
A Canadian Phase II clinical trial led by the University of Calgary is currently investigating hydroxychloroquine’s ability to prevent the worsening of walking ability in adults with PPMS. The study includes 35 participants taking 400 mg daily over 18 months. Researchers are measuring progress using the Timed 25-Foot Walk test as the primary outcome.
Preliminary findings are encouraging, showing a reduction in disability progression among those treated with hydroxychloroquine. These results highlight its potential as a treatment option for PPMS. However, further research through randomized controlled trials is essential to confirm these benefits.
For more detailed information, visit the original article on MS Canada’s website: Hydroxychloroquine and PPMS